Very excited to share this project >2 years in the making! Drug-releasing intravesical floating technology (DRIFT) allowing for synchronous delivery yet sequential exposure Could help existing and novel combination regimens! @BladderCancerUS @SUO_YUO @IBCG_BladderCA

Almost every case we find something occult on blue light that is subtle or missed on white Hard to believe that would not have a positive impact on outcomes (especially with NMIBC outcomes broadly improving in trials/centers of excellence) @RutgersCancer @saumyg

1/4 IMVIGOR011 shows ctDNA is a useful predictive and prognostic tool post cystectomy in muscle invasive bladder cancer #ESMO25 . ctDNA positive patients had DFS and OS benifits with atezolizumab. ctDNA negative patients are at a low risk of relapse/cancer death. @OncoAlert

How do you tailor NMIBC care to the individual, not just the disease? In Episode 2 of our NMIBC Creator Weekend™ series, @SimaPorten @pjhensley11 and @VigneshPackiam discuss patient-centered approaches in bladder cancer care @Ferring #URO266 https://t.co/yZpMJCneJR

Incredible accomplishment to complete these studies!!! IMO not worth it for almost all patients to be subject to high grade IO toxicity risk for a 5% 2-year benefit (primarily with recurrence not progression)

🔥@UrolOncol: November issue! Comparative outcomes of radical nephroureterectomy and kidney-sparing surgery in the treatment of high-grade upper tract urothelial carcinoma Click here to read the #OpenAccess article ▶️ https://t.co/2JSrirqWVR

Great 🧵 on an important paper and topic. Now that there are multiple options for BGC-U NMIBC, need to find a way to sequence them. Cost will be an important piece of that. Lucky to have @AmandaMyersMD at @UIowa_urology continuing this great work!

Season 3 of BackTable Tumor Board is LIVE! Our 8-episode deep dive into the complete management of Non-Muscle Invasive Bladder Cancer. This season is your guide to the latest strategies, from diagnosis to advanced therapeutics. Across the season we cover the entire spectrum of

⚡️ Cost-effectiveness of treatments for BCG-unresponsive CIS - analysis from our multicenter IBCG team. Five strategies modeled: 🔹Radical cystectomy (RC) 🔹Pembrolizumab 🔹Nadofaragene firadenovec 🔹Nogapendekin (NAI-BCG) 🔹Gemcitabine + Docetaxel ➡️Comprehensive

It is interesting that re-induction is increasingly acceptable for immunotherapies but not chemotherapy for NMIBC. Some response probably comes from resection and any therapy and I think its hand-waving to say only immunotherapy

Optimizing patient selection and treatment timing for emerging intravesical therapies. @VigneshPackiam @RutgersCancer joins @zklaassen_md @GACancerCenter to discuss a patient case of a 74-year-old male with multifocal CIS. Dr. Packiam reviews the expanding treatment landscape

Blue light cystoscopy detects hidden #BladderCancer after induction therapy. @VigneshPackiam @RutgersCancer joins @UroCancerMD @VUMCurology in this discussion of enhanced surveillance protocols for high-risk #NMIBC following induction therapy, presenting findings from nearly 300

Season 3 of Backtable Tumor Board @_backtableONC covering Non-Muscle Invasive Bladder Cancer has been released with @RutgersCancer @RWJBarnabas Urologic Oncologist Dr. Vignesh Packiam @VigneshPackiam hosting 4 new episodes! ⬇️ Guide to Patient-Centered Counseling in NMIBC Care:

Optimizing TURBT: Balancing surgical skill and advanced technology. @MarkTysonMD @MayoClinic & @VigneshPackiam @RutgersCancer sit down with @UroDocAsh @MDAndersonNews covering practical considerations including catheter management, environmental sustainability, patient-friendly

Optimizing patient selection and treatment timing for emerging intravesical therapies. @VigneshPackiam @RutgersCancer joins @zklaassen_md @GACancerCenter to discuss a patient case of a 74-year-old male with multifocal CIS. Dr. Packiam reviews the expanding treatment landscape

Boarding ✈️ and excited to head to Turin 🇮🇹 ERAS® World Congress (Sept 17–19, 2025) to speak on “Implementation & Administration Challenges in ERAS.” Connecting global leaders in perioperative care 🌍✨ #ERAS2025 @siadaneshmand @saumyg @VigneshPackiam

How fast do #rcc tumor thrombi grow? 📈 In our cohort @MayoUrology (n=141), venous tumor thrombi expanded ~1 cm/month (wide range). Faster growth seen with higher Mayo level, sarcomatoid/rhabdoid features & metastasis. These data can guide pre-op imaging & surgical triage.

Organoids are not science fiction. They are mini-organs built from stem cells, mirroring human biology. From cancer care to drug discovery, they bring medicine closer to the patient, not the mouse. @CellPressNews @OncoAlert #Cancer #science https://t.co/3xMJKKQRqy

Computational histology AI guides treatment selection for #BladderCancer patients. @VigneshPackiam @RutgersCancer joins @UroCancerMD @VUMCurology discussing this innovative test, which analyzes standard H&E slides from pre-treatment TURBT specimens, examining 600-700 microscopic